These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16292890)

  • 21. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulating the tumor microenvironment to improve radiotherapy.
    Maity A
    Retina; 2009 Jun; 29(6 Suppl):S32-3. PubMed ID: 19553796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
    Nicoli S; Ribatti D; Cotelli F; Presta M
    Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A specific antagonist of the p110delta catalytic component of phosphatidylinositol 3'-kinase, IC486068, enhances radiation-induced tumor vascular destruction.
    Geng L; Tan J; Himmelfarb E; Schueneman A; Niermann K; Brousal J; Fu A; Cuneo K; Kesicki EA; Treiberg J; Hayflick JS; Hallahan DE
    Cancer Res; 2004 Jul; 64(14):4893-9. PubMed ID: 15256460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
    Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
    BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
    Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.
    Shinohara ET; Geng L; Tan J; Chen H; Shir Y; Edwards E; Halbrook J; Kesicki EA; Kashishian A; Hallahan DE
    Cancer Res; 2005 Jun; 65(12):4987-92. PubMed ID: 15958537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
    Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
    Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapy: creating a unique "window" of opportunity.
    Lin MI; Sessa WC
    Cancer Cell; 2004 Dec; 6(6):529-31. PubMed ID: 15607955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.